Research
Insurance, HSA and FSA: why this is a cash-pay category
Coverage and tax-advantaged accounts run on two different tests, and most of this market fails one and can pass the other. The coverage question turns on approval. The account question turns on whether something was prescribed, which is not the same thing at all.
Why the answer is structural rather than a matter of shopping around
People ask whether insurance covers peptide therapy expecting the answer to vary by plan, the way it varies for a physical therapist or a specialist visit.
For most of what is sold in this category the answer does not turn on the plan. It turns on a feature of the product that no amount of shopping changes.
Two different rules are usually being asked about at once. One decides whether a health plan pays. The other decides whether money from a tax-advantaged account can be used.
They are written by different bodies and they ask different questions, so it is worth separating them before looking either one up.
The coverage question runs through approval
Drug benefit rules are built on top of approved products, and the definitions show it plainly.
The federal definition of a Part D drug is a worked example. It is a closed list, and it begins by requiring that a drug be used for a medically accepted indication, which is itself a defined term. The first category it admits is a drug that may be dispensed only upon a prescription and that is described in specified paragraphs of the Social Security Act.
Definitions of that shape work by pointing at categories of approved products. They do not work by asking what a patient wants or what a seller is willing to prepare.
Set that against what the agency says about compounded preparations. Compounded drugs are not approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.
That is the structural reason this category is sold for cash. A benefit design keyed to approved products has nothing to attach to when a preparation sits outside the approval regime.
The approved-drug side of this market is a different situation
This is where a blanket answer would be wrong, and where readers most often get misled in both directions.
Some compounds tracked here have approved products behind them, prescribed for approved indications. That is an ordinary prescription-drug situation, and whether a plan pays depends on the plan, its formulary and its rules.
Compounded preparations of the same molecules are not the same article for this purpose. This site has a separate article on what the shortage rule allowed and when, and one on the difference between approved, off-label, unapproved and compounded status.
So the honest framing is not that nothing here is ever covered. It is that coverage tracks approval, and most of what is marketed in this category sits outside it.
The account question asks something else entirely
Tax-advantaged accounts are governed by the rules on medical expenses, and those rules do not ask whether a drug is approved.
The published guidance is short. You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual, and except for insulin, amounts paid for a drug that is not prescribed cannot be included.
The test is a prescription, not an approval. That is why the two questions come apart, and it is why sellers in this category can accept funds from these accounts while no health plan is paying anything.
The same guidance excludes nutritional supplements, vitamins, herbal supplements and so-called natural medicines, unless recommended by a medical practitioner as treatment for a specific medical condition diagnosed by a physician. Products in this market are sometimes marketed as supplements, and the agency has said of one such group that although they are generally marketed as dietary supplements, they are not dietary supplements.
A vial bought without a prescription is a different situation again, and this site has an article on what a research-use-only label means.
Accepting a card at checkout is not a ruling
Several sellers in this category advertise that they accept funds from these accounts, and that line is easy to over-read.
What it describes is a payment arrangement at the point of sale. It is a fact about the checkout, not a determination that a particular purchase is a qualifying medical expense.
Whether an expense qualifies is decided by the published rules, applied by your plan administrator, and it can be revisited later with substantiation. The seller is not the body that decides it.
This matters more here than in most categories, because the same seller may list preparations that arrive with a prescription alongside products that do not.
Keeping the documentation that shows what was prescribed and by whom is the practical consequence. This site does not give tax advice, and anyone relying on an account for a purchase of this kind should confirm the treatment with their plan administrator or a tax adviser.
What cash-pay does to a price you are reading
Once a category is paid for out of pocket, the advertised figure is the whole figure, and nothing is absorbing any part of it.
That removes the usual cushion. In a covered category a confusing price is often smoothed out by a benefit design before a patient sees it. Here it is not.
It also means fees that would be invisible elsewhere land directly on the buyer. Membership charges, consultation charges and lab arrangements are all part of what is being paid, and this site has an article on reading a price in this category and where those pieces hide.
The comparison unit this site uses wherever it can be established is price per milligram, because that is the unit that survives two sellers describing the same compound differently.
What to check before assuming either answer
Establish which question you are asking. Whether a plan pays and whether an account may be used are different tests with different answers.
For the coverage question, ask whether there is an approved product and an approved indication behind what you are being offered, because benefit definitions are built on those.
For the account question, the published test is whether the drug was prescribed. Ask whether what you are buying arrives against a prescription written for you.
Do not treat a seller's acceptance of account funds as a determination that the expense qualifies. It describes the checkout.
Read the whole price rather than the headline. In a cash-pay category the membership, consultation and lab arrangements are part of what you pay.
Anything about your own treatment comes from your prescriber and the labeling supplied with your medication, and anything about your own tax position comes from your plan administrator or a tax adviser.
Key takeaways
- Plan coverage and tax-advantaged account eligibility are two different tests with two different answers.
- Benefit definitions are built on approved products; the Part D definition requires a medically accepted indication and admits statutory categories.
- The agency has stated that compounded drugs are not approved and that it does not verify their safety, effectiveness or quality.
- Where an approved product is prescribed for an approved indication, that is an ordinary prescription-drug situation.
- The published medical-expense test for a drug is whether it was prescribed, not whether it was approved.
- Except for insulin, amounts paid for a drug that is not prescribed cannot be included as a medical expense.
- Nutritional supplements are excluded unless recommended by a practitioner for a diagnosed condition.
- A seller accepting account funds describes its checkout, not a determination that an expense qualifies.
- In a cash-pay category the advertised figure carries the membership, consultation and lab arrangements too.
Frequently asked questions
Does insurance cover peptide therapy?
For the compounded preparations that make up most of this category, coverage rules have nothing to attach to. Benefit definitions are built on approved products, and the agency has stated that compounded drugs are not approved and that it does not verify their safety, effectiveness or quality before they are marketed. Where an approved product is prescribed for an approved indication, that is an ordinary prescription-drug situation and depends on the plan and its formulary.
Why is this category always sold as cash-pay?
Because the approval question sits upstream of the coverage question. The federal definition of a Part D drug is a worked example of the pattern: it requires use for a medically accepted indication and admits categories of products defined by statute. A definition of that shape points at approved products, so a preparation outside the approval regime is not reached by it.
Can I use HSA or FSA money for peptides?
The published test is whether the drug was prescribed, not whether it was approved. The guidance states that you can include amounts paid for prescribed medicines and drugs. It defines a prescribed drug as one that requires a prescription by a doctor for its use by an individual. Except for insulin, amounts paid for a drug that is not prescribed cannot be included. This site does not give tax advice, so confirm your own situation with your plan administrator or a tax adviser.
A seller says it accepts HSA and FSA funds. Does that settle it?
No. That describes a payment arrangement at checkout rather than a determination that a purchase is a qualifying medical expense. The published rules decide that, your plan administrator applies them, and substantiation can be requested later. It matters here because the same seller may list preparations that arrive with a prescription alongside products that do not.
What about products sold as supplements?
The medical expense guidance excludes nutritional supplements, vitamins, herbal supplements and natural medicines unless recommended by a medical practitioner as treatment for a specific medical condition diagnosed by a physician. Marketing something as a supplement also does not make it one. The agency has said of bodybuilding products containing selective androgen receptor modulators that although they are generally marketed as dietary supplements, they are not dietary supplements but unapproved drugs.
Does cash-pay change how I should read a price?
It removes the cushion. Nothing is absorbing part of the figure before you see it, so membership charges, consultation charges and lab arrangements land directly on the buyer. This site compares on price per milligram wherever that can be established, and has a separate article on where the other pieces of a price in this category tend to sit.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration, September 2025
- 42 CFR 423.100, Definitions — Office of the Federal Register, Electronic Code of Federal Regulations, June 2026
- Publication 502 (2025), Medical and Dental Expenses, for use in preparing 2025 returns — Internal Revenue Service, January 2025
- Bodybuilding Products: SARMs Cause Harm — U.S. Food and Drug Administration, December 2025